How has MoonLake Immunotherapeutics's deferred contract costs changed year-over-year?

MoonLake Immunotherapeutics's deferred contract costs decreased by 20.8% year-over-year, from $1.7M to $1.34M.

MoonLake Immunotherapeutics MLTX Deferred contract costs

Deferred contract costs at other companies

Nano Nuclear EnergyNNE

$385.5K—

KEE

Keel Infrastructure Corp. Common StockKEEL

$1.67M—

MatsonsMATX

$99.1M+27.4%

National Fuel GasNFG

$81.33M+16.9%

Universal Health ServicesUHS

$9.23M+0.5%

TeraWulfWULF

$572.77M—

Other financials

Income statement

See full

Operating income-$70.0M-47.5%

Net income-$69.7M-74.5%

EPS (diluted)-$0.98-55.6%

Balance sheet

See full

Cash & equivalents$298.5M+9.9%

Total debt$100.8M+33.3%

Total equity$254.0M-37.7%

Total assets$400.4M-21.7%

Cash flow

See full

Operating cash flow-$66.3M-73.8%

CapEx--100%

Free cash flow-$66.3M-73.6%

Valuation

See full

Market cap$1.49B-45.9%

Enterprise value$1.29B-50.0%

Returns & leverage

See full

Return on equity-77.7%-221pp

Debt / equity0.4×+0.2×

Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:DeferredCosts.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's deferred contract costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MoonLake Immunotherapeutics's deferred contract costs?: MoonLake Immunotherapeutics (MLTX) reported deferred contract costs of $1.34M in Q1 2026.
How has MoonLake Immunotherapeutics's deferred contract costs changed year-over-year?: MoonLake Immunotherapeutics's deferred contract costs decreased by 20.8% year-over-year, from $1.7M to $1.34M.